ArticleBMC cancer2018
Burden of early, advanced and metastatic breast cancer in The Netherlands.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The value of case reports in rare oncological scenarios: mixed method analysis of colorectal metastases from breast cancer.Clinical & experimental metastasis · 2023Pooled it
- Cancers: What Are the Costs in Relation to Disability-Adjusted Life Years? A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- Psychometric Properties of the Turkish Version of the EORTC QLQ-ELD14 in Older Patients With Cancer.International journal of nursing practice · 2026Article
- Factors influencing discussion duration in breast cancer multidisciplinary team meetings: insights for streamlining care.Breast cancer research and treatment · 2026Article
- International comparisons of survival after recurrent metastatic breast cancer in four countries: A population-based study.Breast (Edinburgh, Scotland) · 2026Article
- Impact of screening on late-stage breast cancer in the Netherlands: a population-based cohort study (2007-2016).Breast (Edinburgh, Scotland) · 2026Article
- Review
- Article
- Productivity losses from short-term work absence due to neoplasms in Poland.Scientific reports · 2024Article
- Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice.Medicina (Kaunas, Lithuania) · 2024Review
- Article
- Estimating the Disability-Adjusted Life-Years (DALYs) of Five Most Prevalent Cancers in the Elderly in Markazi Province, Iran, 2019.Medical journal of the Islamic Republic of Iran · 2024Article
- Factors affecting the economic burden of breast cancer in southern Iran.BMC health services research · 2023Article
- Cost-effectiveness of 2-[Scientific reports · 2023Article
- Cost-Effectiveness Analysis of MammaPrintPharmacoEconomics · 2023Article
- Clinical and Translational Applications of Serological and Histopathological Biomarkers in Metastatic Breast Cancer: A Comprehensive Review.International journal of molecular sciences · 2023Review
- Association of Stroke at Young Age With New Cancer in the Years After Stroke Among Patients in the Netherlands.JAMA network open · 2023Article
- Economic burden of breast cancer in northern Serbia.Frontiers in public health · 2023Article
- A systemmatic literature review on indirect costs of women with breast cancer.Cost effectiveness and resource allocation : C/E · 2022Review
- Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modelled strategies.International journal of cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to estimate the total economic and health related burden of breast cancer in the Netherlands.
methodsData on incidence, prevalence, mortality and survival were extracted from the Dutch National Cancer Registry and were used to calculate the economic and health related burden of breast cancer for overall, DCIS (stage 0), early- (stage I), locally advanced- (stage II-III) and metastatic- (stage IV) breast cancer by age groups and by year (if applicable).
resultsThe overall incidence of breast cancer increased from 103.4 up to 153.2 per 100,000 women between 1990 and 2014. The increase was driven by DCIS and early breast cancer as the incidence of locally advanced and metastatic breast cancer remained stable. Between 1990 and 2014, ten-year overall survival rates increased from 87% to 93% for early breast cancer, 41% to 62% for locally advanced- and from 6% to 9% for metastatic disease. Annually, breast cancer in the Netherlands is responsible for approximately 3100 deaths, 26,000 life years lost, 65,000 Disability Adjusted Life Years (DALYs) and an economic burden of €1.27 billion.
conclusionsThis study provides a comprehensive assessment of the burden of breast cancer and subsequent trends over time in the Netherlands.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.